#### AYERS JONATHAN W

Form 4

August 16, 2017

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

5 D L (\* 1 \* CD - (\* D - ( ) (

January 31, 2005

0.5

of

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16.

Check this box

Form 4 or Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1 Name and Address of Departing D

1. Name and Address of Reporting Person * AYERS JONATHAN W				2. Issuer Name and Ticker or Trading Symbol IDEXX LABORATORIES INC /DE [IDXX]					5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
	(Last)		(Middle)	(Month/	Day/Year)	Γransaction		_	X Director X Officer (give titelow)		Owner (specify	
	ONE IDEA	XX DRIVE		08/14/2017					Chairman, President & CEO			
(Street)				Filed(Month/Day/Year)				6.	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
	WESTBRO	OOK, ME 04092						Pe	_ Form filed by Morerson	e than One Rep	oorting	
	(City)	(State)	(Zip)	Tal	ole I - Non-	Derivative	Securitie	es Acquii	ed, Disposed of, o	or Beneficiall	y Owned	
	1.Title of	2. Transaction Date	2A. Deeme	ed	3.	4. Securiti	es Acquir	red (A) or	5. Amount of	6.	7. Nature o	
	Security	(Month/Day/Year)	Execution	Date, if	Transactio	nDisposed	of (D)		Securities	Ownership	Indirect	
	(Instr. 3)		any		Code	(Instr. 3, 4	and 5)		Beneficially	Form:	Beneficial	
			(Month/Da	y/Year)	(Instr. 8)				Owned	Direct (D)	Ownership	
									Following	or Indirect	(Instr. 4)	
							(A)		Reported	(I)		
							or		Transaction(s)	(Instr. 4)		
					Code V	Amount		Drice	(Instr. 3 and 4)			

		(Month/Day/Year)	(Instr. 8)		(A) or		Owned Following Reported Transaction(s)	Direct or Ind (I) (Instr.
			Code V	Amount	(D)	Price	(Instr. 3 and 4)	
Common Stock	08/14/2017		M	18,000	A	\$ 38.795	1,043,034	D
Common Stock	08/14/2017		S	18,000	D	\$ 154.9076 <u>(1)</u>	1,025,034	D
Common Stock	08/14/2017		M	2,000	A	\$ 38.795	1,027,034	D
Common Stock	08/15/2017		M	14,900	A	\$ 38.795	1,041,934	D
Common Stock	08/15/2017		S	14,900	D	\$ 154.7146	1,027,034	D

### Edgar Filing: AYERS JONATHAN W - Form 4

					(2)			
Common Stock	08/15/2017	M	5,100	A	\$ 38.795	1,032,134	D	
Common Stock	08/15/2017	S	5,100	D	\$ 154.3334 (3)	1,027,034	D	
Common Stock	08/15/2017	M	2,000	A	\$ 38.795	1,029,034	D	
Common Stock	08/16/2017	M	20,000	A	\$ 38.795	1,049,034	D	
Common Stock	08/16/2017	S	20,000 (4)	D	\$ 155.4744	1,029,034	D	
Common Stock	08/16/2017	M	2,000	A	\$ 38.795	1,031,034	D	
Common Stock						98,000	I	by Ayers Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	TransactionDerivative Code Securities		cisable and ate 'Year)	7. Title and Underlying S (Instr. 3 and	Securit
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sh
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/14/2017		M	18,000	(5)	02/13/2018	Common Stock	18,0
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/14/2017		M	2,000	<u>(5)</u>	02/13/2018	Common Stock	2,0
Non-Qualified Stock Option	\$ 38.795	08/15/2017		M	14,900	<u>(5)</u>	02/13/2018	Common Stock	14,9

(9-02)

(right-to-buy)								
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/15/2017	M	5,100	<u>(5)</u>	02/13/2018	Common Stock	5,1
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/15/2017	M	2,000	(5)	02/13/2018	Common Stock	2,0
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/16/2017	M	20,000	(5)	02/13/2018	Common Stock	20,0
Non-Qualified Stock Option (right-to-buy)	\$ 38.795	08/16/2017	M	2,000	<u>(5)</u>	02/13/2018	Common Stock	2,0

## **Reporting Owners**

Reporting Owner Name / Address	Relationships							
reporting o where remains a remainder	Director	10% Owner	Officer	Other				
AYERS JONATHAN W ONE IDEXX DRIVE WESTBROOK, ME 04092	X		Chairman, President & CEO					

# **Signatures**

/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W.
Ayers

08/16/2017

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents the weighted average sales price of the shares sold ranging from a low of \$154.80 to a high of \$155.00 per share. The (1) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$154.50 to a high of \$154.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$154.25 to a high of \$154.40 per share. The (3) undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Represents the weighted average sales price of the shares sold ranging from a low of \$155.08 to a high of \$156.025 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Grant of option to buy 200,000 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2012 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

Reporting Owners 3

### Edgar Filing: AYERS JONATHAN W - Form 4

#### (6) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.